Renal Insufficiency, Chronic Clinical Trial
— NEPHRACTIVEOfficial title:
Highlighting the Medico-economic Interest of an Adapted Physical Activity for Haemodialysis Patients
Verified date | June 2022 |
Source | Clinique Néphrologique Saint-Exupéry |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Chronic hemodialysis is often associated with a reduction in the quality of life of patients and a reduction in physical activity, due to the repeated frequency of sessions. Various studies conducted in hemodialysis patients have shown the beneficial effects of physical exercise during hemodialysis sessions on reducing cardiovascular risk, the number of hospitalizations and improving quality of life. It also contributes to improved patient adherence to care. Finally, it has been shown that exercise during the hemodialysis session is safe for the patient and does not disrupt dialysis parameters. Nevertheless, there are no data on the medico-economic impact of such a program. Based on the investigators' experience, the investigators have developed a specific protocol linking the different types of physical activity that have provided evidence of their efficiency and used in standard practice in the investigators' institutions. From tests and questionnaires assessing the physical abilities of patients have already validated for this population in this pathology. The objective of this project is to show the medico-economic interest of an adapted physical activity program for hemodialysis patients.
Status | Completed |
Enrollment | 52 |
Est. completion date | June 4, 2022 |
Est. primary completion date | June 4, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patient dependent on the CPAM Haute Garonne, - Patient affiliated to or beneficiary of a French social security scheme, - Haemodialysis patient for more than 12 months and in front of benefiting/benefiting from a physical activity program, - Patient age = at 18 years old, - French speaking patient. Exclusion Criteria: - Patient with cancer, hepatitis, stage 4 arterial disease, arteritis or amputation of a limb - Pregnant or breastfeeding women according to article L.1121-5 of the CSP, - Vulnerable persons according to article L.1121-6 of the CSP, - Persons of full age under guardianship or curatorship or under safeguard of justice, - Patient unable to personally give his or her consent, or age of majority protected by law, - Opposition expressed to inclusion in the study. |
Country | Name | City | State |
---|---|---|---|
France | Clinique Néphrologique Saint Saint-Exupéry | Toulouse |
Lead Sponsor | Collaborator |
---|---|
Clinique Néphrologique Saint-Exupéry |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Variation in direct and indirect medical costs | Evaluation of medical costs between the 12 months prior to the start of the adapted physical activity program and the 12 months following the start of the adapted physical activity program. | through study completion, an average of 1 year | |
Secondary | change in the quality of life score | Assessed by a The Short Form (36) (SF-36 scale) interpreted by an algorythm | baseline, at 6 months and at one year | |
Secondary | change in body mass index, weight and height will be combined to report BMI in kg/m^2 | obtained in start of hemodialysis session | every month, up to 12 months | |
Secondary | change in blood presure in mmHg | obtained in start of hemodialysis session | every month, up to 12 months | |
Secondary | change in rate of haemoglobin in g/dL | obtained in start of hemodialysis session | every month, up to 12 months | |
Secondary | change in percentage of hematocrit and saturation coefficient in % | obtained in start of hemodialysis session | every month, up to 12 months | |
Secondary | change in rate of ferritin in ug/L | obtained in start of hemodialysis session | every month, up to 12 months | |
Secondary | change in rate of urea, transferrin and blood sugar in g/L | obtained in start of hemodialysis session | every month, up to 12 months | |
Secondary | change in rate of potassium in mEq/L | obtained in start of hemodialysis session | every month, up to 12 months | |
Secondary | change in rate of bicarbonate in mmol/L | obtained in start of hemodialysis session | every month, up to 12 months | |
Secondary | change in rate of calcium, phosphore and C-reactiv protein in mg/L | obtained in start of hemodialysis session | every month, up to 12 months | |
Secondary | change in physical activity evaluation score, from 0 (better) to 20 (worse) | obtained thanks to Borg scale | baseline, at 6 months and at one year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT05056727 -
A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia
|
Phase 3 | |
Withdrawn |
NCT01655186 -
A Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Effects of Bardoxolone Methyl on Body Composition in Patients With Stage 4 Chronic Kidney Disease and Type 2 Diabetes Mellitus
|
Phase 2 | |
Completed |
NCT03481686 -
Therapeutic Education of Chronic Renal or Renal Transplant Patient in the Management of EPO Injections
|
N/A | |
Active, not recruiting |
NCT03672110 -
Slow and Low Start of a Tacrolimus Once Daily Immunosuppressive Regimen
|
Phase 3 | |
Enrolling by invitation |
NCT02237534 -
Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia
|
Phase 4 | |
Completed |
NCT02126293 -
Correction of Zinc Deficiency in Children With Chronic Kidney Disease and Kidney Transplant
|
Phase 3 | |
Terminated |
NCT01533545 -
Effect of Epinephrine on Systemic Absorption of Mepivacaine in Uremic Patients
|
N/A | |
Completed |
NCT03280615 -
Omega 3 Fatty Acids in Patients With Chronic Renal Disease
|
Phase 3 | |
Completed |
NCT04498156 -
Survey of Patient and Physician Awareness and Values to the Diagnosis and Treatment of Reduced Kidney Function (Chronic Kidney Disease) in Patients With High Blood Sugar Level (Type 2 Diabetes) (AWARE-CKD in T2D)
|
||
Recruiting |
NCT04020328 -
Leflunomide Plus Low Dose Corticosteroid in Immunoglobulin A (IgA) Nephropathy With Renal Insufficiency
|
Phase 4 | |
Recruiting |
NCT06366529 -
Explore New Magnetic Resonance Technology in Assessment of Renal Dysfunction
|
||
Active, not recruiting |
NCT04876963 -
HOLT-ED: Holter-monitoring in End-stage Renal Disease
|
||
Completed |
NCT03836508 -
Effect of Dialysis Membranes on Inflammatory and Immune Processes in Hemodialysis
|
N/A | |
Completed |
NCT03250715 -
Effects of Low Level Laser Therapy on Functional Capacity and DNA Damage of Patients With Chronic Kidney Failure
|
N/A | |
Completed |
NCT03577249 -
Biological Effects of Citrate-buffered Solutions on Dialysis Efficiency and Systemic Inflammation
|
Phase 2/Phase 3 | |
Completed |
NCT01975818 -
Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934
|
Phase 2 | |
Active, not recruiting |
NCT05766644 -
App-based Education Program for CKD
|
N/A | |
Active, not recruiting |
NCT02791880 -
Acute Kidney Injury Genomics and Biomarkers in TAVR Study
|
||
Recruiting |
NCT02947750 -
Neurovascular Transduction During Exercise in Chronic Kidney Disease
|
Phase 2 | |
Terminated |
NCT02286258 -
Validation of New Markers of Glomerular Filtration Rate: Dota Gadolinium and Calcium EDTA (MultiGFR)
|
Phase 1/Phase 2 |